Urogen Pharma (NASDAQ:URGN) Holdings Lowered by Jefferies Financial Group Inc.

Key Points

• Jefferies Financial Group Inc. reduced its holdings in Urogen Pharma by 15.6%, owning 815,000 shares after selling 150,929 shares in the first quarter.
• Urogen Pharma reported a loss of ($0.92) EPS for the quarter, missing estimates, and had a negative net margin of 150.68% with revenue of $20.25 million.
• Analysts have set a consensus target price of $32.86 for Urogen Pharma, with several firms issuing "buy" ratings following recent updates.

Jefferies Financial Group Inc. lowered its position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 15.6% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 815,000 shares of the company's stock after selling 150,929 shares during the quarter. Jefferies Financial Group Inc. owned about 1.77% of Urogen Pharma worth $9,014,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in shares of Urogen Pharma in the 4th quarter valued at approximately $59,000. Wellington Management Group LLP raised its position in shares of Urogen Pharma by 7.0% in the 4th quarter. Wellington Management Group LLP now owns 146,953 shares of the company's stock valued at $1,565,000 after purchasing an additional 9,653 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Urogen Pharma by 751.5% in the 4th quarter. Alliancebernstein L.P. now owns 199,259 shares of the company's stock valued at $2,122,000 after purchasing an additional 175,859 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Urogen Pharma by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 461,902 shares of the company's stock valued at $4,919,000 after purchasing an additional 6,265 shares in the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Urogen Pharma in the 4th quarter valued at approximately $358,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

Insider Buying and Selling at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 7,522 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the transaction, the general counsel owned 41,492 shares of the company's stock, valued at approximately $794,156.88. This represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Mark Schoenberg sold 5,149 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $98,551.86. Following the completion of the transaction, the insider directly owned 158,229 shares of the company's stock, valued at approximately $3,028,503.06. The trade was a 3.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,833 shares of company stock worth $280,567 over the last ninety days. 5.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on URGN. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the company a "buy" rating in a research report on Friday, June 13th. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Guggenheim reissued a "buy" rating and set a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. Finally, D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a research report on Monday, July 7th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.86.

Urogen Pharma Stock Up 1.8%

NASDAQ URGN traded up $0.34 during trading hours on Friday, hitting $19.40. The company had a trading volume of 1,007,990 shares, compared to its average volume of 1,235,309. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $19.74. The business has a fifty day simple moving average of $12.21 and a 200-day simple moving average of $10.96. The firm has a market cap of $896.28 million, a P/E ratio of -6.10 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. Equities analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.